Nanexas signs agreement with global pharmaceutical company for evaluation of PharmaShell®

Pressrelease

 

Uppsala 10thSeptember 2019

 

Nanexas signs agreement with global pharmaceutical company for evaluation of PharmaShell®

 

Nanexa has today signed a Material Transfer and Feasibility study Agreement with an unnamed global pharmaceutical company. The company runs a product development project where the goal is an injectable product that releases drugs over 4 -12 weeks. The purpose of the now signed agreement is for the company to conduct an initial evaluation of PharmaShell® as a drug delivery system for this product.

 

The agreement regulates, among other things, details of what is to be investigated and clarification of patent rights as well as a stipulated minor compensation that accrues to Nanexa for this evaluation.

 

The company’s CEO David Westberg comments:

We have been discussing this opportunity with the company for a while and I am now very pleased that we have signed this agreement and can get started with the practical work. It is an exciting project and I look forward to the upcoming evaluation.

 

 

For further information:

Nanexa AB (publ)

David Westberg, VD

Phone: +46 709 42 83 03

E mail: david.westberg@nanexa.se

www.nanexa.com

 

About Nanexa AB (publ)

Nanexa AB is a nanotechnology drug delivery company focusing on the development of PharmaShell®, which is a new and groundbreaking drug delivery system that is expected to have great potential in a number of medical indications. Within the framework of PharmaShell®, Nanexa has partnership agreements with among others, AstraZeneca.